Printer Friendly

ONCOR, INC. REPORTS OPERATING RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 1993

 GAITHERSBURG, Md., Nov. 5 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR) reported increased sales for the third quarter and nine months ended Sept. 30, 1993.
 Gross revenues in the third quarter of 1993 increased by 16 percent to $2.0 million, compared with $1.8 million for the third quarter of 1992. The company recorded a net loss of $3.0 million or $0.19 per share in the third quarter of 1993, compared with a net loss of $1.5 million or $0.10 per share in the same period of 1992. The increased loss for 1993 was primarily the result of greater investment in research and development, including clinical trials to support FDA applications.
 For the nine months ended Sept. 30, 1993, gross revenues increased by 29 percent to $6.1 million compared with $4.7 million in the same period of 1992. Net loss for the nine month period was $8.1 million or $0.52 per share compared with a net loss of $6.4 million or $0.44 per share in the same period of 1992. The loss for the 1992 nine month period included a net charge of $1.4 million or $0.11 per share in order to terminate royalty payments required under a research and development contract.
 As of Sept. 30, 1993, the company had cash, cash equivalents and short-term investments of approximately $18.5 million.
 Stephen Turner, chairman and chief executive officer, commented, "As anticipated, we are pleased that our revenues and gross profits continue to increase with a 29 percent sales increase in the first nine months of 1993, attributable to our new product launches and increased demand for our existing DNA probe kits. Our gross profits as a percentage of product sales increased to 55 percent in the first nine months of 1993 from 43 percent in the same period of 1992."
 "We are pleased to report that clinical trials of our DNA probes for use in the diagnosis of breast cancer, bladder cancer, chronic myelogenous leukemia (CML) and acute promyelocytic leukemia (APL) are being completed on schedule. We anticipate that the data from our existing and planned clinical studies will be sufficient to support our planned PMA applications to the FDA in late 1993 and early 1994 for the first gene-based tests for breast cancer, CML, APL, and bladder cancer," Mr. Turner concluded.
 Oncor develops, manufactures and markets Human Genome-based test systems for use in the early detection and management of cancer and other genetic diseases.
 ONCOR, INC.
 Consolidated Statements Of Operations
 (unaudited)
 Three Months Ended Nine Months Ended
 9/30/93 9/30/92 9/30/93 9/30/92
 GROSS REVENUES:
 Product Sales $1,979,984 $1,653,402 $6,020,997 $4,600,850
 Grants 55,000 99,649 55,000 99,649
 Total Revenues 2,034,984 1,753,051 6,075,997 4,700,499
 Direct cost of sales 878,186 822,260 2,725,996 2,608,951
 Gross Profit 1,156,798 930,791 3,350,001 2,091,548
 56 pct 50 pct 55 pct 43 pct
 OPERATING EXPENSES:
 Selling, general
 and administrative 1,820,271 1,430,135 5,355,695 3,900,640
 Research and
 development 2,457,817 1,333,472 6,627,589 3,906,230
 Buyout of research and
 development contract -- -- -- 1,446,820
 Total operating
 expenses 4,278,088 2,763,607 11,983,284 9,253,690
 LOSS FROM
 OPERATIONS (3,121,290) (1,832,816) (8,633,283) (7,162,142)
 OTHER INCOME (EXPENSE) 149,190 305,411 520,638 810,853
 Net loss (2,972,100) (1,527,405) (8,112,645) (6,351,289)
 NET LOSS PER SHARE ($0.19) ($0.10) ($0.52) ($0.44)
 WEIGHTED-AVERAGE
 COMMON SHARES
 OUTSTANDING 15,667,302 14,930,739 15,533,597 14,404,585
 -0- 11/5/93
 /CONTACT: Naomi Rosenfeld or Betsy Brod of Morgen-Walke Associates 212-850-5600/
 (ONCR)


CO: Oncor, Inc. ST: Maryland IN: MTC SU: ERN

LD -- NY003 -- 1083 11/05/93 08:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1993
Words:673
Previous Article:SHAWMUT NATIONAL AGREES TO ACQUIRE GATEWAY FINANCIAL IN STOCK DEAL VALUED AT $152 MILLION
Next Article:PHARMACEUTICAL RESOURCES ANNOUNCES PLAN TO RELAUNCH PREVIOUSLY APPROVED PRODUCTS IN FY'94 -- PAR SUBSIDIARY WILL BEGIN MARKETING METRONIDAZOLE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters